SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer

被引：0
|
作者：
Mayer, Ingrid A. [1 ]
Abramson, Vandana [1 ]
Balko, Justin [1 ]
Sanders, Melinda [1 ]
Juric, Dejan [2 ]
Solit, David [3 ]
Li, Yisheng [4 ]
Cantley, Lewis [5 ]
Winer, Eric [6 ]
Arteaga, Carlos [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Weill Cornell Med Coll, New York, NY USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-CT232
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT232
引用
收藏
页数：3
相关论文
共 50 条
  • [1] SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Balko, Justin M.
    Sanders, Melinda
    Juric, Dejan
    Li, Yisheng
    Ley, Lewis Cant
    Winer, Eric P.
    Arteag, Carlos L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer
    Mayer, Ingrid A.
    Abramson, Vandana G.
    Formisano, Luigi
    Balko, Justin M.
    Estrada, Monica V.
    Sanders, Melinda E.
    Juric, Dejan
    Solit, David
    Berger, Michael F.
    Won, Helen H.
    Li, Yisheng
    Cantley, Lewis C.
    Winer, Eric
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2017, 23 (01) : 26 - 34
  • [3] SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Balko, Justin M.
    Isakoff, Steven J.
    Kuba, Maria Gabriela
    Sanders, Melinda
    Forero-Torres, Andres
    Yap, Jeffrey T.
    Van Den Abbeele, Annick D.
    Li, Yisheng
    Arteaga, Carlos L.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2-Metastatic Breast Cancer (MBC).
    Mayer, I. A.
    Balko, J. M.
    Kuba, M. G.
    Sanders, M. E.
    Yap, J.
    Li, Y.
    Winer, E.
    Arteaga, C. L.
    CANCER RESEARCH, 2011, 71
  • [5] Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, Her2-breast cancer.
    Munster, Pamela N.
    Hamilton, Erika Paige
    Estevez, Laura G.
    De Boer, Richard H.
    Mayer, Ingrid A.
    Campone, Mario
    Asano, Shizuka
    Bhansali, Suraj
    Zhang, Vickie
    Hewes, Becker
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [6] Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2-breast cancer: Safety, preliminary efficacy and molecular analysis
    Juric, Dejan
    Hamilton, Erika
    Garcia Estevez, Laura
    De Boer, Richard H.
    Mayer, Ingrid
    Campone, Mario
    Asano, Shizuka
    Bhansali, Suraj
    Zhang, Vickie
    Hewes, Becker
    Munster, Pamela
    CANCER RESEARCH, 2015, 75
  • [7] Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Diana G. Wang
    Dulce M. Barrios
    Victoria S. Blinder
    Jacqueline F. Bromberg
    Pamela R. Drullinsky
    Samuel A. Funt
    Komal L. Jhaveri
    Diana E. Lake
    Tomas Lyons
    Shanu Modi
    Pedram Razavi
    Michelle Sidel
    Tiffany A. Traina
    Linda T. Vahdat
    Mario E. Lacouture
    Breast Cancer Research and Treatment, 2020, 183 : 227 - 237
  • [8] Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Wang, Diana G.
    Barrios, Dulce M.
    Blinder, Victoria S.
    Bromberg, Jacqueline F.
    Drullinsky, Pamela R.
    Funt, Samuel A.
    Jhaveri, Komal L.
    Lake, Diana E.
    Lyons, Tomas
    Modi, Shanu
    Razavi, Pedram
    Sidel, Michelle
    Traina, Tiffany A.
    Vandat, Linda T.
    Lacouture, Mario E.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 227 - 237
  • [9] Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer
    Janku, Filip
    Juric, Dejan
    Cortes, Javier
    Rugo, Hope
    Burris, Howard A.
    Schuler, Martin
    Deschler-Baier, Barbara
    Middleton, Mark R.
    Gil-Martin, Marta
    Berlin, Jordan
    Winer, Eric
    Bootle, Douglas
    Blumenstein, Lars
    Demanse, David
    Coughlin, Christina
    Quadt, Cornelia
    Baselga, Jose
    CANCER RESEARCH, 2015, 75
  • [10] P6-10-05: SU2C Phase 1 b Trial of Dual mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2-Metastatic Breast Cancer (MBC)
    Mayer, I. A.
    Abramson, V. G.
    Balko, J. M.
    Isakoff, S. J.
    Forero, A.
    Kuba, M. G.
    Sanders, M. E.
    Li, Y.
    Winer, E.
    Arteaga, C. L.
    CANCER RESEARCH, 2012, 72
12345